cisplatin,pembrolizumab,gemcitabine
merck
['pembro', 'cisplatin', 'hcrn gu14-188', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'gemcitabine']
hcrn gu14-188: ph1b/2 of neoadj gem/cis/pembro (cohort a: cis-eligible) or gem/pembro (b:cis-ineligible) in miuc pair: 61% &amp; 52% pcr: 44% &amp; 45% rc or rnu: 88% &amp; 87% 18mo rfs: 82% &amp; 65% 36mo os: 79% &amp; 66% gr3+ ae: anemia (30%), htn (28%), neutrop (25%)
#gu23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @AUB_Lebanon and @MCG_Urology